1. Home
  2. TFX vs ABVX Comparison

TFX vs ABVX Comparison

Compare TFX & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TFX
  • ABVX
  • Stock Information
  • Founded
  • TFX 1943
  • ABVX 2013
  • Country
  • TFX United States
  • ABVX France
  • Employees
  • TFX N/A
  • ABVX N/A
  • Industry
  • TFX Medical/Dental Instruments
  • ABVX
  • Sector
  • TFX Health Care
  • ABVX
  • Exchange
  • TFX Nasdaq
  • ABVX Nasdaq
  • Market Cap
  • TFX 5.1B
  • ABVX 5.3B
  • IPO Year
  • TFX N/A
  • ABVX N/A
  • Fundamental
  • Price
  • TFX $130.32
  • ABVX $84.01
  • Analyst Decision
  • TFX Hold
  • ABVX Strong Buy
  • Analyst Count
  • TFX 9
  • ABVX 8
  • Target Price
  • TFX $141.57
  • ABVX $90.63
  • AVG Volume (30 Days)
  • TFX 566.9K
  • ABVX 1.2M
  • Earning Date
  • TFX 10-30-2025
  • ABVX 08-11-2025
  • Dividend Yield
  • TFX 1.04%
  • ABVX N/A
  • EPS Growth
  • TFX N/A
  • ABVX N/A
  • EPS
  • TFX 4.18
  • ABVX N/A
  • Revenue
  • TFX $3,041,342,000.00
  • ABVX $7,073,400.00
  • Revenue This Year
  • TFX $10.16
  • ABVX $25.23
  • Revenue Next Year
  • TFX $10.10
  • ABVX N/A
  • P/E Ratio
  • TFX $31.37
  • ABVX N/A
  • Revenue Growth
  • TFX 1.11
  • ABVX N/A
  • 52 Week Low
  • TFX $108.90
  • ABVX $4.77
  • 52 Week High
  • TFX $249.91
  • ABVX $92.91
  • Technical
  • Relative Strength Index (RSI)
  • TFX 60.05
  • ABVX 67.94
  • Support Level
  • TFX $128.32
  • ABVX $82.72
  • Resistance Level
  • TFX $133.18
  • ABVX $91.30
  • Average True Range (ATR)
  • TFX 2.62
  • ABVX 3.62
  • MACD
  • TFX 0.12
  • ABVX -1.13
  • Stochastic Oscillator
  • TFX 69.51
  • ABVX 47.89

About TFX Teleflex Incorporated

Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Share on Social Networks: